Verve Therapeutics, Inc. Operating Lease, Payments in USD from Q1 2021 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Verve Therapeutics, Inc. quarterly/annual Operating Lease, Payments history and growth rate from Q1 2021 to Q1 2025.
  • Verve Therapeutics, Inc. Operating Lease, Payments for the quarter ending March 31, 2025 was $2.72M, a 2.88% increase year-over-year.
  • Verve Therapeutics, Inc. annual Operating Lease, Payments for 2024 was $10.6M, a 15.6% decline from 2023.
  • Verve Therapeutics, Inc. annual Operating Lease, Payments for 2023 was $12.6M, a 149% increase from 2022.
  • Verve Therapeutics, Inc. annual Operating Lease, Payments for 2022 was $5.05M, a 150% increase from 2021.
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, YoY Quarterly Growth (%)
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Growth (%)

Verve Therapeutics, Inc. Quarterly Operating Lease, Payments (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $2.72M +$76K +2.88% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q1 2024 $2.64M -$507K -16.1% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q1 2023 $3.15M +$2.62M +495% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 $529K +$55K +11.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q1 2021 $474K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10

Verve Therapeutics, Inc. Annual Operating Lease, Payments (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $10.6M -$1.96M -15.6% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 $12.6M +$7.5M +149% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 $5.05M +$3.03M +150% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 $2.02M Jan 1, 2021 Dec 31, 2021 10-K 2023-03-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.